|
13 Jan 2022 |
Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC)
|
|
13 Jan 2022 |
Vaxxinity Announces First Parkinson’s Disease Patient Dosed in Part B of Phase 1 Clinical Trial of UB-312
|
|
07 Jan 2022 |
Anokion Announces Progress Across Pipeline of Novel Autoimmune Programs
|
|
06 Jan 2022 |
Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine
|
|
05 Jan 2022 |
Leiden University Medical Center and Intravacc to Start Clinical Trial with New Intranasal Corona Vaccine
|
|
05 Jan 2022 |
Gritstone Announces Positive Clinical Results from First Cohort of a Phase 1 Study (CORAL-BOOST) Evaluating a T Cell-Enhanced Self-Amplifying mRNA (samRNA) Vaccine Against COVID-19
|
|
31 Dec 2021 |
Johnson & Johnson COVID-19 Vaccine Demonstrates 85 Percent Effectiveness against Hospitalization in South Africa when Omicron was Dominant
|
|
28 Dec 2021 |
Nykode Therapeutics announces first subject dosed with its T cell focused next-generation SARS-CoV-2 vaccine candidate
|
|
23 Dec 2021 |
Vaxzevria significantly boosted antibody levels against Omicron
|
|
22 Dec 2021 |
AFFiRiS and Frontier Biotechnologies announce license agreement for AFFITOPE®AT04, an active immunotherapy targeting PCSK9 to treat hypercholesterolemia, in Greater China
|
|
22 Dec 2021 |
Novavax Announces Initiation of PREVENT-19 COVID-19 Vaccine Phase 3 Trial Booster Study
|
|
20 Dec 2021 |
European Commission Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine
|
|
20 Dec 2021 |
Moderna Announces Preliminary Booster Data and Updates Strategy to Address Omicron Variant
|
|
17 Dec 2021 |
Emergent BioSolutions Announces Initiation of Phase 1 Study Evaluating Its Universal Influenza Vaccine Candidate
|
|
17 Dec 2021 |
Arcturus Therapeutics Reports New Data and Provides Additional Updates from ARCT-154 and ARCT-165 Clinical Trials
|
|
16 Dec 2021 |
Valneva Announces Positive Homologous Booster Data for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001
|
|
15 Dec 2021 |
European Commission Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Individuals 18 Years of Age and Older
|
|
15 Dec 2021 |
Sumitomo Dainippon Pharma Oncology Provides Update on Phase 3 WIZARD 201G Study of Ombipepimut-S Emulsion (DSP-7888) in Patients with Recurrent or Progressive Glioblastoma
|
|
15 Dec 2021 |
Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation
|
|
11 Dec 2021 |
Moderna Announces Positive Interim Phase 1 Data for mRNA Flu Vaccine and Provides Program Update
|
|
08 Dec 2021 |
I-Mab Announces First Patient Dosed in U.S. Phase 1 Study of Protollin for the Treatment of Alzheimer's Disease
|
|
07 Dec 2021 |
Medicago and GSK announce positive Phase 3 efficacy and safety results for adjuvanted plant-based COVID-19 vaccine candidate
|
|
06 Dec 2021 |
Bavarian Nordic Reports Positive Topline Phase 2 Results for its COVID-19 Vaccine Candidate
|
|
06 Dec 2021 |
Johnson & Johnson COVID-19 Booster, Administered Six Months After Two-Dose Regimen of BNT162b2, Shows Substantial Increase in Antibody and T-cell Responses
|
|
03 Dec 2021 |
Valneva Confirms Initiation of Rolling Review with EMA and Provides Updates on its COVID-19 Vaccine Program VLA2001
|
